Fundraising FoxPulse Biosciences
NASDAQ: PLSEBurlingame, US · Founded 2014 · Delaware corporation · 1 known investors
Find your way into Pulse Biosciences
Sign up to see every warm intro you have to Pulse Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pulse Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pulse Biosciences develops and commercializes ablation systems based on nanosecond pulsed-field ablation technology to treat medical conditions including benign skin lesions, soft tissue tumors, and cardiac arrhythmias. The company manufactures the nPulse System and associated disposable applicators for use in surgical, endoscopic, and catheter-based procedures across multiple medical specialties.
Founders & leadership
Board
Investors · 1
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$93M disclosed across 4 rounds · 2014–2021
▶$50MraisedJul 2021 · 1 investors · Other Health CareRule 506(b)
- Richard van den BroekDirector
- Kenneth ClarkDirector
- Sandra GardinerExecutive Officer
- Robert DugganDirector
- Edward EbbersExecutive Officer
- Mitchell LevinsonDirector
- Manmeet SoniDirector
- Darrin UeckerExecutive Officer, Director
- Mahkam ZanganehDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Minimum investment
- $50M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
- Mitchell E. LevinsonDirector
- Thierry B. ThaureDirector
- Brian B. DowExecutive Officer
- Darrin UeckerExecutive Officer, Director
- Robert J. GreenbergDirector
- Maky ZanganehDirector
- Robert LevandeDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada, 2014
- Federal exemptions
- 06b
▶$5MraisedFeb 2017 · 2 investors · BiotechnologyRule 506(b)
- Mitchell E. LevinsonDirector
- Brian B. DowExecutive Officer
- Maky ZanganehDirector
- Robert M. LevandeDirector, Promoter
- Darrin R. UeckerExecutive Officer, Director
- Thierry B. ThaureDirector
- Robert J. GreenbergDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Feb 2017
- Incorporated
- Corporation, Nevada, 2014
- Federal exemptions
- 06b
▶$8MraisedNov 2014 · 72 investors · BiotechnologyRule 506(b)
- Amy WangExecutive Officer, Director
- Robert LevandeExecutive Officer, Director
- Christopher MarlettDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $800K
- Placement agents
- MDB Capital Group, LLC
- First sale
- Nov 2014
- Incorporated
- Corporation, Nevada, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Pulse Biosciences do?
- Pulse Biosciences develops and commercializes ablation systems based on nanosecond pulsed-field ablation technology to treat medical conditions including benign skin lesions, soft tissue tumors, and cardiac arrhythmias. The company manufactures the nPulse System and associated disposable applicators for use in surgical, endoscopic, and catheter-based procedures across multiple medical specialties.
- Who are Pulse Biosciences's investors?
- Pulse Biosciences's investors include SV Health Investors.
- How much funding has Pulse Biosciences raised?
- Pulse Biosciences has disclosed $93M raised across 4 rounds.
- Where is Pulse Biosciences headquartered?
- Pulse Biosciences is headquartered in Burlingame, US.